Skip to main content

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced that its Board of Directors has suspended the Company’s previously announced share repurchase program.

Under the now suspended share repurchase program, the Company repurchased approximately 520,000 shares of common stock for an aggregate purchase price of approximately $7.5 million. Following these repurchases, the Company had approximately 12.8 million shares of common stock outstanding.

GLSI Announces Suspension of Share Repurchase Program


Company Contact

Snehal Patel

Investor Relations

Office: (832) 819-3232


Investor & Public Relations Contact for Greenwich LifeSciences

Dave Gentry

RedChip Companies Inc.

Office: 1-800-RED CHIP (733 2447)

Cell: (407) 491-4498


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.